-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Lunan Pharmaceutical, which started with traditional Chinese medicine, won the company's second listed biological produ.
With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.
With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.
After winning 3 major varieties, the second biological drug is coming
Recently, the official website of NMPA shows that Lunan Pharmaceutical Group Shandong New Era Pharmaceutical's insulin glargine injection has been approved for marketing, becoming the fifth domestic compa.
At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.
At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.
Insulin glargine injection belongs to the third-generation insulin, which has the effect of long-acting, no peak in blood concentration, and stable blood sugar reduction of patien.
According to the data of Min.
com, the domestic market of insulin glargine has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.
A year-on-year increase of 0
According to the data of Min.
com, the domestic market of insulin glargine has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.
A year-on-year increase of 0
Products approved by Lunan Pharmaceutical since the beginning of this year
Source: MED0 China Drug Evaluation Database
In addition to insulin glargine injection, Lunan Pharmaceutical has also approved two varieties of enoxaparin sodium injection and metformin hydrochloride sustained-release tablets since the beginning of this year, which are deemed to have passed the consistency evaluati.
Among them, enoxaparin sodium injection is the market leader of low molecular weight heparin preparations, with terminal sales of more than 6 billion yuan in Chinese public medical institutions in 202 Enoxaparin sodium injection is expected to be included in the eighth batch of centralized procurement, and Lunan Pharmaceutical is the fifth company that has passed the evaluatio.
It is worth mentioning that insulin glargine injection, enoxaparin sodium injection, and metformin hydrochloride sustained-release tablets have performed well in terminal sales in Chinese public medical institutions in recent years, and Lunan Pharmaceutical is expected to take a sha.
29 varieties have been reviewed! 14 new products on the way
Up to now, 29 varieties (37 specifications) of Lunan Pharmaceutical have passed/deemed to pass the consistency evaluati.
7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.
For exclusive revi.
7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.
For exclusive revi.
The 29 reviewed varieties are mainly concentrated in digestive system and metabolizing drugs (6), cardiovascular and cerebrovascular drugs (6), anti- tumor and immunomodulators (
Lunan Pharmaceutical passed/deemed to pass the consistency evaluation varieties
Source: MED0 China Drug Evaluation Database
In the first five batches of centralized procurement carried out by the state, 4 varieties of Lunan Pharmaceutical's Cetirizine Hydrochloride Tablets, Mosapride Citrate Tablets, Isosorbide Mononitrate Sustained-Release Tablets, and Rivaroxaban Tablets were obtain.
Eligibili.
Eligibili.
Among the seventh batch of varieties to be collected, Lunan Pharmaceutical's Milrinone Injection, Tirofiban Hydrochloride Injection/Tirofiban Hydrochloride Concentrated Solution for Injection, Isosorbide Mononitrate Tablets, and Omeprazole for Injecti.
Sodium will participate in the biddi.
Sodium will participate in the biddi.
In terms of supplementary applications for consistency evaluation, Lunan Pharmaceutical has 12 varieties (16 acceptance numbers) in the state of “under review and approval”, including epirubicin hydrochloride for injection, imipenem and cilastatin sodium for injection, and Lilistat Capsules, Cetylpyridinium Chloride Lozenges,e.
In terms of new registration classification applications, Lunan Pharmaceutical has 14 varieties (18 acceptance numbers) marketing applications under review, and will be deemed to have passed the consistency evaluation after being approved for producti.
Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.
Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.
Among the 14 varieties to be approved, two varieties, Sapropterin Hydrochloride Tablets and Vonola Fumarate Raw Tablets, have not been approved as generic drugs in the domestic mark.
Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.
Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.
Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.
Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.
Lunan Pharmaceutical's new registration classification is under review
Source: MED0 China Drug Evaluation Database
9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine
As a comprehensive pharmaceutical group integrating the production, research and sales of pharmaceuticals, chemical drugs and biological products, Lunan Pharmaceutical Group aims to "maintain the advantages of chemical pharmaceuticals, vigorously develop traditional Chinese medicine, and strengthen biopharmaceuticals .
Innovative drugs in immune diseases and other fiel.
Innovative drugs in immune diseases and other fiel.
In recent years, Lunan Pharmaceutical has continued to increase investment in scientific resear.
In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.
In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.
Lunan Pharmaceutical's innovative drugs in clinical stage
Source: MED0 China Drug Evaluation Database
In the field of Chinese patent medicines, Jingfang Mixture has been approved for clinical use for urticaria such as skin rash and itchi.
Jingfang Mixture comes from ancient prescriptio.
Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.
Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.
This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.
Jingfang Mixture comes from ancient prescriptio.
Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.
Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.
This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.
In the field of chemical drugs, Lunan Pharmaceutical's class 1 new drug LL-10 has been approved for clinical use, and class 2 improved new drugs, vornorasan fumarate injection and mosapride citrate injection, are exclusively deployed in Chi.
Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.
At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.
Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.
At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.
In the field of biological products, Lunan Pharmaceutical's long-acting Baisheng medicine has been put on the market, and insulin glargine has been approved for production; the biosimilar recombinant anti-CD20 human-mouse chimeric monoclonal antibody injection is in phase III clinical; 4 new drugs of class 1 PD-1 monoclonal antibody, BCMA/CD3 double antibody, CD47 monoclonal antibody, LNF1904 are in clinical progress; more than 20 new class 1 biological drugs are being developed, and strive to launch a biological product every year in the next 3-5 yea.
Data source: Minet database
Note: The statistics are as of May 1 If there are any omissions, please correct me!
Recently, Lunan Pharmaceutical, which started with traditional Chinese medicine, won the company's second listed biological produ.
With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.
With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.
After winning 3 major varieties, the second biological drug is coming
Recently, the official website of NMPA shows that Lunan Pharmaceutical Group Shandong New Era Pharmaceutical's insulin glargine injection has been approved for marketing, becoming the fifth domestic compa.
At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.
At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.
Insulin glargine injection belongs to the third-generation insulin, which has the effect of long-acting, no peak in blood concentration, and stable blood sugar reduction of patien.
According to the data of Min.
com, the domestic market of insulin glargine has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.
A year-on-year increase of 0
According to the data of Min.
com, the domestic market of insulin glargine has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.
A year-on-year increase of 0
Products approved by Lunan Pharmaceutical since the beginning of this year
Source: MED0 China Drug Evaluation Database
In addition to insulin glargine injection, Lunan Pharmaceutical has also approved two varieties of enoxaparin sodium injection and metformin hydrochloride sustained-release tablets since the beginning of this year, which are deemed to have passed the consistency evaluati.
Among them, enoxaparin sodium injection is the market leader of low molecular weight heparin preparations, with terminal sales of more than 6 billion yuan in Chinese public medical institutions in 202 Enoxaparin sodium injection is expected to be included in the eighth batch of centralized procurement, and Lunan Pharmaceutical is the fifth company that has passed the evaluatio.
It is worth mentioning that insulin glargine injection, enoxaparin sodium injection, and metformin hydrochloride sustained-release tablets have performed well in terminal sales in Chinese public medical institutions in recent years, and Lunan Pharmaceutical is expected to take a sha.
29 varieties have been reviewed! 14 new products on the way
Up to now, 29 varieties (37 specifications) of Lunan Pharmaceutical have passed/deemed to pass the consistency evaluati.
7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.
For exclusive revi.
7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.
For exclusive revi.
The 29 reviewed varieties are mainly concentrated in digestive system and metabolizing drugs (6), cardiovascular and cerebrovascular drugs (6), anti- tumor and immunomodulators (
Lunan Pharmaceutical passed/deemed to pass the consistency evaluation varieties
Source: MED0 China Drug Evaluation Database
In the first five batches of centralized procurement carried out by the state, 4 varieties of Lunan Pharmaceutical's Cetirizine Hydrochloride Tablets, Mosapride Citrate Tablets, Isosorbide Mononitrate Sustained-Release Tablets, and Rivaroxaban Tablets were obtain.
Eligibili.
Eligibili.
Among the seventh batch of varieties to be collected, Lunan Pharmaceutical's Milrinone Injection, Tirofiban Hydrochloride Injection/Tirofiban Hydrochloride Concentrated Solution for Injection, Isosorbide Mononitrate Tablets, and Omeprazole for Injecti.
Sodium will participate in the biddi.
Sodium will participate in the biddi.
In terms of supplementary applications for consistency evaluation, Lunan Pharmaceutical has 12 varieties (16 acceptance numbers) in the state of “under review and approval”, including epirubicin hydrochloride for injection, imipenem and cilastatin sodium for injection, and Lilistat Capsules, Cetylpyridinium Chloride Lozenges,e.
In terms of new registration classification applications, Lunan Pharmaceutical has 14 varieties (18 acceptance numbers) marketing applications under review, and will be deemed to have passed the consistency evaluation after being approved for producti.
Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.
Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.
Among the 14 varieties to be approved, two varieties, Sapropterin Hydrochloride Tablets and Vonola Fumarate Raw Tablets, have not been approved as generic drugs in the domestic mark.
Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.
Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.
Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.
Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.
Lunan Pharmaceutical's new registration classification is under review
Source: MED0 China Drug Evaluation Database
9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine
As a comprehensive pharmaceutical group integrating the production, research and sales of pharmaceuticals, chemical drugs and biological products, Lunan Pharmaceutical Group aims to "maintain the advantages of chemical pharmaceuticals, vigorously develop traditional Chinese medicine, and strengthen biopharmaceuticals .
Innovative drugs in immune diseases and other fiel.
Innovative drugs in immune diseases and other fiel.
In recent years, Lunan Pharmaceutical has continued to increase investment in scientific resear.
In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.
In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.
Lunan Pharmaceutical's innovative drugs in clinical stage
Source: MED0 China Drug Evaluation Database
In the field of Chinese patent medicines, Jingfang Mixture has been approved for clinical use for urticaria such as skin rash and itchi.
Jingfang Mixture comes from ancient prescriptio.
Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.
Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.
This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.
Jingfang Mixture comes from ancient prescriptio.
Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.
Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.
This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.
In the field of chemical drugs, Lunan Pharmaceutical's class 1 new drug LL-10 has been approved for clinical use, and class 2 improved new drugs, vornorasan fumarate injection and mosapride citrate injection, are exclusively deployed in Chi.
Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.
At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.
Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.
At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.
In the field of biological products, Lunan Pharmaceutical's long-acting Baisheng medicine has been put on the market, and insulin glargine has been approved for production; the biosimilar recombinant anti-CD20 human-mouse chimeric monoclonal antibody injection is in phase III clinical; 4 new drugs of class 1 PD-1 monoclonal antibody, BCMA/CD3 double antibody, CD47 monoclonal antibody, LNF1904 are in clinical progress; more than 20 new class 1 biological drugs are being developed, and strive to launch a biological product every year in the next 3-5 yea.
Data source: Minet database
Note: The statistics are as of May 1 If there are any omissions, please correct me!
Recently, Lunan Pharmaceutical, which started with traditional Chinese medicine, won the company's second listed biological produ.
With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.
With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.
After winning 3 major varieties, the second biological drug is coming
After winning 3 major varieties, the second biological drug is coming Recently, the official website of NMPA shows that Lunan Pharmaceutical Group Shandong New Era Pharmaceutical's insulin glargine injection has been approved for marketing, becoming the fifth domestic compa.
At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.
At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.
Insulin glargine injection belongs to the third-generation insulin, which has the effect of long-acting, no peak in blood concentration, and stable blood sugar reduction of patien.
According to the data of Min.
com, the domestic market of insulin glargine has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.
A year-on-year increase of 0
hospital hospital hospitalAccording to the data of Min.
com, the domestic market of insulin glargine has continued to expand in recent yea.
In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.
A year-on-year increase of 0
Products approved by Lunan Pharmaceutical since the beginning of this year
Source: MED0 China Drug Evaluation Database
In addition to insulin glargine injection, Lunan Pharmaceutical has also approved two varieties of enoxaparin sodium injection and metformin hydrochloride sustained-release tablets since the beginning of this year, which are deemed to have passed the consistency evaluati.
Among them, enoxaparin sodium injection is the market leader of low molecular weight heparin preparations, with terminal sales of more than 6 billion yuan in Chinese public medical institutions in 202 Enoxaparin sodium injection is expected to be included in the eighth batch of centralized procurement, and Lunan Pharmaceutical is the fifth company that has passed the evaluatio.
enterprise enterprise enterprise It is worth mentioning that insulin glargine injection, enoxaparin sodium injection, and metformin hydrochloride sustained-release tablets have performed well in terminal sales in Chinese public medical institutions in recent years, and Lunan Pharmaceutical is expected to take a sha.
29 varieties have been reviewed! 14 new products on the way
29 varieties have been reviewed! 14 new products on the way Up to now, 29 varieties (37 specifications) of Lunan Pharmaceutical have passed/deemed to pass the consistency evaluati.
7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.
For exclusive revi.
7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.
For exclusive revi.
The 29 reviewed varieties are mainly concentrated in digestive system and metabolizing drugs (6), cardiovascular and cerebrovascular drugs (6), anti- tumor and immunomodulators (
tumor tumor tumor Lunan Pharmaceutical passed/deemed to pass the consistency evaluation varieties
Source: MED0 China Drug Evaluation Database
In the first five batches of centralized procurement carried out by the state, 4 varieties of Lunan Pharmaceutical's Cetirizine Hydrochloride Tablets, Mosapride Citrate Tablets, Isosorbide Mononitrate Sustained-Release Tablets, and Rivaroxaban Tablets were obtain.
Eligibili.
Eligibili.
Among the seventh batch of varieties to be collected, Lunan Pharmaceutical's Milrinone Injection, Tirofiban Hydrochloride Injection/Tirofiban Hydrochloride Concentrated Solution for Injection, Isosorbide Mononitrate Tablets, and Omeprazole for Injecti.
Sodium will participate in the biddi.
Sodium will participate in the biddi.
In terms of supplementary applications for consistency evaluation, Lunan Pharmaceutical has 12 varieties (16 acceptance numbers) in the state of “under review and approval”, including epirubicin hydrochloride for injection, imipenem and cilastatin sodium for injection, and Lilistat Capsules, Cetylpyridinium Chloride Lozenges,e.
In terms of new registration classification applications, Lunan Pharmaceutical has 14 varieties (18 acceptance numbers) marketing applications under review, and will be deemed to have passed the consistency evaluation after being approved for producti.
Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.
Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.
Among the 14 varieties to be approved, two varieties, Sapropterin Hydrochloride Tablets and Vonola Fumarate Raw Tablets, have not been approved as generic drugs in the domestic mark.
Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.
Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.
Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.
Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.
Lunan Pharmaceutical's new registration classification is under review
Source: MED0 China Drug Evaluation Database
9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine
9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine As a comprehensive pharmaceutical group integrating the production, research and sales of pharmaceuticals, chemical drugs and biological products, Lunan Pharmaceutical Group aims to "maintain the advantages of chemical pharmaceuticals, vigorously develop traditional Chinese medicine, and strengthen biopharmaceuticals .
Innovative drugs in immune diseases and other fiel.
disease disease diseaseInnovative drugs in immune diseases and other fiel.
In recent years, Lunan Pharmaceutical has continued to increase investment in scientific resear.
In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.
In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.
Lunan Pharmaceutical's innovative drugs in clinical stage
Source: MED0 China Drug Evaluation Database
In the field of Chinese patent medicines, Jingfang Mixture has been approved for clinical use for urticaria such as skin rash and itchi.
Jingfang Mixture comes from ancient prescriptio.
Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.
Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.
This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.
Jingfang Mixture comes from ancient prescriptio.
Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.
Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.
This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.
In the field of chemical drugs, Lunan Pharmaceutical's class 1 new drug LL-10 has been approved for clinical use, and class 2 improved new drugs, vornorasan fumarate injection and mosapride citrate injection, are exclusively deployed in Chi.
Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.
At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.
Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.
At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.
In the field of biological products, Lunan Pharmaceutical's long-acting Baisheng medicine has been put on the market, and insulin glargine has been approved for production; the biosimilar recombinant anti-CD20 human-mouse chimeric monoclonal antibody injection is in phase III clinical; 4 new drugs of class 1 PD-1 monoclonal antibody, BCMA/CD3 double antibody, CD47 monoclonal antibody, LNF1904 are in clinical progress; more than 20 new class 1 biological drugs are being developed, and strive to launch a biological product every year in the next 3-5 yea.
Data source: Minet database
Note: The statistics are as of May 1 If there are any omissions, please correct me!